Cargando…

Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

BACKGROUND: This study was conducted to identify whether the presence of circulating tumor DNA (ctDNA) in plasma before treatment with EGFR‐tyrosine kinase inhibitors (TKIs) is associated with clinical outcomes. METHODS: Fifty‐seven pairs of tissues and plasma samples were obtained from patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yunkyoung, Park, Sojung, Kim, Woo Sung, Lee, Jae Cheol, Jang, Se Jin, Choi, Jene, Choi, Chang‐Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119619/ https://www.ncbi.nlm.nih.gov/pubmed/29989342 http://dx.doi.org/10.1111/1759-7714.12793

Ejemplares similares

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
por: Kim, Hye-Ryoun, et al.
Publicado: (2013)

Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer
por: Bulbul, Ajaz, et al.
Publicado: (2020)

Data of ‘Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage’
por: Kirchweger, Patrick, et al.
Publicado: (2022)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
por: Douillard, Jean-Yves, et al.
Publicado: (2014)

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
por: Park, Song Ee, et al.
Publicado: (2019)

Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery
por: Yang, Lu, et al.
Publicado: (2020)

Circulating lncRNA EGFR-AS1 as a diagnostic biomarker of colorectal cancer and an indicator of tumor burden
por: Dai, Weiping, et al.
Publicado: (2022)

Selective killing of circulating tumor cells prevents metastasis and extends survival
por: Kim, Yi Rang, et al.
Publicado: (2018)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
por: Xu, Xiaojing, et al.
Publicado: (2020)

Correction to: Selective killing of circulating tumor cells prevents metastasis and extends survival
por: Kim, Yi Rang, et al.
Publicado: (2019)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
por: Zhu, Guanhua, et al.
Publicado: (2021)

Tumor Stage-Related Role of Radiotherapy in Patients with an External Auditory Canal and Middle Ear Carcinoma
por: Choi, Jinhyun, et al.
Publicado: (2017)

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2016)

High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival
por: Kujala, Jouni, et al.
Publicado: (2020)

Tumor budding as a predictor of disease-free survival in patients with cholangiocarcinoma
por: Kim, Kyung Bin, et al.
Publicado: (2023)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer
por: Wang, Dong, et al.
Publicado: (2019)

Microfluidic Chip-Based Cancer Diagnosis and Prediction of Relapse by Detecting Circulating Tumor Cells and Circulating Cancer Stem Cells
por: Cho, Hyeon-Yeol, et al.
Publicado: (2021)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma
por: Kim, Yeseul, et al.
Publicado: (2023)

Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
por: Yang, Xin, et al.
Publicado: (2022)

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
por: Lee, R J, et al.
Publicado: (2018)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study
por: Li, Shih-Hong, et al.
Publicado: (2022)

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021)

Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer
por: Xu, Hongming, et al.
Publicado: (2022)

Cell-free circulating tumor DNA in cancer
por: Qin, Zhen, et al.
Publicado: (2016)

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms
por: Jeong, Sun Young, et al.
Publicado: (2023)

Overexpression of the NEK9–EG5 axis is a novel metastatic marker in pathologic stage T3 colon cancer
por: Kim, Meejeong, et al.
Publicado: (2023)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Circulating Microparticles and Coagulation Profiles in Patients with Advanced Stage Solid Tumors
por: Sun, Der Sheng, et al.
Publicado: (2018)

Intronic variant of EGFR is associated with GBAS expression and survival outcome of early‐stage non‐small cell lung cancer
por: Hong, Mi Jeong, et al.
Publicado: (2018)

ARL2 is required for homologous recombination repair and colon cancer stem cell survival
por: Lee, Hani, et al.
Publicado: (2022)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer
por: Lee, Tae Hee, et al.
Publicado: (2021)

Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
por: Gast, Charles E., et al.
Publicado: (2018)

Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) Expression as a Prognostic Marker in Adult Supratentorial Diffuse Astrocytic and Oligodendroglial Tumors
por: Jeong, Hui Jeong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kgmc05vfap1irt8a43s1q3b725